185
Views
4
CrossRef citations to date
0
Altmetric
Clinical Trial Evaluation

Treating multiple sclerosis with fingolimod or intramuscular interferon

Evaluation of ‘Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.’ N Engl J Med 2010;362:402-15. [Epub ahead of print]

, MD PhD, , MD & , MD
Pages 1957-1960 | Published online: 28 Apr 2010

Bibliography

  • Cohen JA, Barkhof F, Comi G, Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
  • Kappos L, Antel J, Comi G, Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355:1124-40
  • O'Connor P, Comi G, Montalban X, Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology 2009;72:73-9
  • Montalban X, O'Connor P, Antel G, Oral fingolimod (FTY720) shows sustained low rates of clinical and MRI disease activity in patients with relapsing multiple sclerosis: four-year results from a phase II extension. Neurology 2009;72(Suppl 3):A313
  • Kappos L, Radue EW, O'Connor P, ; FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
  • Gasperini C, Cefaro LA, Borriello G, Emerging oral drugs for multiple sclerosis. Expert Opin Emerg Drugs 2008;13:465-77
  • Mikol DD, Barkhof F, Chang P, ; REGARD study group. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008;7:903-14
  • O'Connor P, Filippi M, Arnason B, ; BEYOND Study Group. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009;8:889-97
  • Herr DR, Chun J. Effects of LPA and S1P on the nervous system and implications for their involvement in disease. Curr Drug Targets 2007;8:155-67
  • Miron VE, Jung CG, Kim HJ, FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol 2008;63:61-71
  • Storch M, Rausch M, Hiestand P, FTY720 not only prevents EAE onset, as assessed by MRI, but also reverses established neurological deficits and extensive demyelination. Presented at the 22nd ECTRIMS congress. Mult Scler 2006;12(Suppl 2):P188

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.